Skip to main content
DMTXinactive

Dimension Therapeutics, Inc.

Biopharma developer (SEC filing verified)·Pre-clinical·CEO: Dimension Therapeutics
Rare DiseaseHematology

DMTX evidence brief

What we can confirm

BioSniper Score:
6.0 / 10
Lead Asset:
dtx101 (Preclinical)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 6.0 / 10 · Lead Asset: dtx101 (Preclinical)
BioSniper AIPage evidence connected

Prepared research question

What matters most for DMTX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

6.0/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

dtx101 (Preclinical)

Next Catalyst

—

Tracking 7 pipeline candidates for Dimension Therapeutics, Inc..

Run Dimension Therapeutics, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Dimension Therapeutics, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is Dimension Therapeutics, Inc.'s lead drug candidate?

Dimension Therapeutics, Inc.'s most advanced tracked candidate is dtx101 (Preclinical) for hemophilia B.

Who is the CEO of Dimension Therapeutics, Inc.?

Dimension Therapeutics is the chief executive officer of Dimension Therapeutics, Inc. (DMTX).

What therapeutic areas does Dimension Therapeutics, Inc. focus on?

Dimension Therapeutics, Inc. develops therapies across Rare Disease, Hematology.

923 companies304,844 SEC filings22,644 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.